203 related articles for article (PubMed ID: 36162852)
21. Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.
Ho PJ; Ho WK; Khng AJ; Yeoh YS; Tan BK; Tan EY; Lim GH; Tan SM; Tan VKM; Yip CH; Mohd-Taib NA; Wong FY; Lim EH; Ngeow J; Chay WY; Leong LCH; Yong WS; Seah CM; Tang SW; Ng CWQ; Yan Z; Lee JA; Rahmat K; Islam T; Hassan T; Tai MC; Khor CC; Yuan JM; Koh WP; Sim X; Dunning AM; Bolla MK; Antoniou AC; Teo SH; Li J; Hartman M
BMC Med; 2022 Apr; 20(1):150. PubMed ID: 35468796
[TBL] [Abstract][Full Text] [Related]
22. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
Jiao Y; Truong T; Eon-Marchais S; Mebirouk N; Caputo SM; Dondon MG; Karimi M; Le Gal D; Beauvallet J; Le Floch É; Dandine-Roulland C; Bacq-Daian D; Olaso R; Albuisson J; Audebert-Bellanger S; Berthet P; Bonadona V; Buecher B; Caron O; Cavaillé M; Chiesa J; Colas C; Collonge-Rame MA; Coupier I; Delnatte C; De Pauw A; Dreyfus H; Fert-Ferrer S; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Golmard L; Lasset C; Lejeune-Dumoulin S; Léoné M; Limacher JM; Lortholary A; Luporsi É; Mari V; Maugard CM; Mortemousque I; Mouret-Fourme E; Nambot S; Noguès C; Popovici C; Prieur F; Pujol P; Sevenet N; Sobol H; Toulas C; Uhrhammer N; Vaur D; Venat L; Boland-Augé A; Guénel P; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Eur J Cancer; 2023 Jan; 179():76-86. PubMed ID: 36509001
[TBL] [Abstract][Full Text] [Related]
23. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
24. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.
Li SX; Milne RL; Nguyen-Dumont T; Wang X; English DR; Giles GG; Southey MC; Antoniou AC; Lee A; Li S; Winship I; Hopper JL; Terry MB; MacInnis RJ
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977228
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
Evans DGR; Harkness EF; Brentnall AR; van Veen EM; Astley SM; Byers H; Sampson S; Southworth J; Stavrinos P; Howell SJ; Maxwell AJ; Howell A; Newman WG; Cuzick J
Breast Cancer Res Treat; 2019 Jul; 176(1):141-148. PubMed ID: 30941651
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.
Lee A; Yang X; Tyrer J; Gentry-Maharaj A; Ryan A; Mavaddat N; Cunningham AP; Carver T; Archer S; Leslie G; Kalsi J; Gaba F; Manchanda R; Gayther S; Ramus SJ; Walter FM; Tischkowitz M; Jacobs I; Menon U; Easton DF; Pharoah P; Antoniou AC
J Med Genet; 2022 Jul; 59(7):632-643. PubMed ID: 34844974
[TBL] [Abstract][Full Text] [Related]
29. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
30. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
31. Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women.
Zirpoli GR; Pfeiffer RM; Bertrand KA; Huo D; Lunetta KL; Palmer JR
Breast Cancer Res; 2024 Jan; 26(1):2. PubMed ID: 38167144
[TBL] [Abstract][Full Text] [Related]
32. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.
Eriksson M; Czene K; Strand F; Zackrisson S; Lindholm P; Lång K; Förnvik D; Sartor H; Mavaddat N; Easton D; Hall P
Radiology; 2020 Nov; 297(2):327-333. PubMed ID: 32897160
[TBL] [Abstract][Full Text] [Related]
33. Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model.
Mavaddat N; Ficorella L; Carver T; Lee A; Cunningham AP; Lush M; Dennis J; Tischkowitz M; Downes K; Hu D; Hahnen E; Schmutzler RK; Stockley TL; Downs GS; Zhang T; Chiarelli AM; Bojesen SE; Liu C; Chung WK; Pardo M; Feliubadaló L; Balmaña J; Simard J; Antoniou AC; Easton DF
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):422-427. PubMed ID: 36649146
[TBL] [Abstract][Full Text] [Related]
34. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
35. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
36. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract][Full Text] [Related]
37. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
38. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
39. Prediction of breast cancer risk for sisters of women attending screening.
Mao X; He W; Eriksson M; Lindström LS; Holowko N; Bajalica-Lagercrantz S; Hammarström M; Grassmann F; Humphreys K; Easton D; Hall P; Czene K
J Natl Cancer Inst; 2023 Nov; 115(11):1310-1317. PubMed ID: 37243694
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
